Leadership Changes at Tessera Therapeutics
Tessera Therapeutics has recently announced changes to its leadership team, highlighting the remarkable journey and future of the biotechnology company renowned for its innovatory Gene Writing™ technology. In a notable transition, Howard Liang has decided to step down as President and Chief Financial Officer, marking the end of a significant chapter in his career after five impactful years with the company.
Howard Liang's Departure and Legacy
Howard’s contributions to Tessera have been pivotal in advancing its vision and strengthening its market position. Michael Severino, M.D., the current CEO, expressed gratitude for Howard's leadership: "Howard has been instrumental in shaping our strategy, advancing our platform, and strengthening Tessera’s foundation for long-term success. We thank him for his significant contributions and wish him every success in his next chapter." After unveiling these transitions, Howard will remain in his position until the end of the year to ensure a seamless handover.
Kathy Bergsteinsson Steps In as CFO
With these changes, Tessera is excited to announce the appointment of Kathy Bergsteinsson as its new Chief Financial Officer. Kathy comes to Tessera with a wealth of experience totaling over 25 years in management, corporate finance, and capital markets. Prior to joining Tessera, she served as CFO at Affini-T Therapeutics and held a significant position at Morgan Stanley, where she was a Managing Director, overseeing Healthcare Equity Capital Markets. Her prior experience includes raising over $100 billion in equity financing through numerous Initial Public Offerings (IPOs) and follow-on offerings.
Kathy's Vision for Tessera
Kathy is poised to bring her strategic insights and financial acumen to Tessera during this essential phase of growth. Speaking about her new role, she enthused, "I am excited to join Tessera at such a pivotal time for the company. The team has built a compelling Gene Writing and delivery platform with the potential to fundamentally reshape genetic medicine. I look forward to partnering with the leadership team to support Tessera's strategic vision, advance its programs, and help position the company for long-term success."
About Tessera Therapeutics
Tessera Therapeutics has made its mark in the biotech sector with innovative approaches to genome engineering, including its Gene Writing™ platform. This technology opens up new possibilities for developing transformative genetic medicines aimed not only at curing diseases linked to single-gene errors but also modifying inherited disease risks and creating engineered cells for treating conditions such as cancer and autoimmune disorders. Founded in 2018 by Flagship Pioneering, Tessera is rapidly advancing its solutions to improve human health and address critical challenges in medicine.
Contact Information
For more information regarding this leadership transition, please reach out to Jonathan Pappas from LifeSci Communications, LLC via email at jpappas@lifescicomms.com.
Frequently Asked Questions
What prompted the leadership changes at Tessera Therapeutics?
The leadership changes were initiated by Howard Liang's decision to step down as President and CFO to pursue new opportunities, leaving a legacy of significant contributions to the company.
Who is the new Chief Financial Officer at Tessera?
Kathy Bergsteinsson has been appointed as the new Chief Financial Officer, bringing over 25 years of finance and management experience.
What is the significance of Tessera's Gene Writing™ platform?
Tessera's Gene Writing™ platform allows for precise modifications in the genome, aiming at transformative treatments for various genetic conditions and diseases.
How long did Howard Liang serve at Tessera Therapeutics?
Howard Liang served as President and CFO for five years, during which he contributed significantly to the company’s growth and strategic positioning.
What does the future hold for Tessera Therapeutics under Kathy's leadership?
Under Kathy's leadership, Tessera aims to continue progressing its Gene Writing initiatives and expand its portfolio in genetic medicine to achieve long-term success.
